<DOC>
	<DOCNO>NCT00404586</DOCNO>
	<brief_summary>This study design look safety aspect effect intranasal dose GW784568X allergic rhinitis symptom develop drug use people suffer allergic rhinitis</brief_summary>
	<brief_title>Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber</brief_title>
	<detailed_description>A randomised , placebo-controlled , 4-period , incomplete block , crossover study 7 day dose intranasal GW784568X ( 100mcg , 200mcg 400mcg od ) , fluticasone propionate ( 200mcg od ) placebo ( blind GW784568X v placebo ) evaluate efficacy safety use environmental chamber male subject allergic rhinitis</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Inclusion criterion : Healthy exception seasonal rhinitis . May also mild asthma . Weight great equal 50kg Nonsmoker least 12 month Exclusion criterion : History frequent nosebleed Have participate another trial last 30 day . Have donate blood previous 3 month Have use prescription non prescription drug within last 7 day Have history alcohol/drug abuse within last 12 month Have positive Hepatitis B C test within 3 month screen Subject test positive HIV</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GW784568X</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Environmental Challenge Chamber</keyword>
</DOC>